Global Markets
J&J downgrades biosimilar threat as Q3 pulls in $10bn+ in pharma sales
Global Markets
J&J downgrades biosimilar threat as Q3 pulls in $10bn+ in pharma salesJ&J downgrades biosimilar threat as Q3 pulls in $10bn+ in pharma sales
J&J reported sales above $10 billion in its pharmaceutical division and has lowered its biosimilar headwind forecast to $2 billion.
Subscribe to receive our monthly print or digital publication
Join our 70,000+ readers. And yes, it's completely free.